Cohort Studymoderate evidence
Longitudinal plasma proteomics predict phenoconversion to clinically manifest ALS.
Nature medicine·July 27, 2026·PMID 42509371
Why it mattersPredicting which pre-symptomatic carriers of ALS-associated variants will develop clinically manifest disease and when remains a major barrier to prevention trials. A validated multi-protein panel could enable risk stratification, earlier intervention, and more efficient trial design in this high-risk population.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled